Advertisement

Adenosine pp 307-322 | Cite as

The Many Roles of Adenosine in Traumatic Brain Injury

  • Patrick M. KochanekEmail author
  • Jonathan D. Verrier
  • Amy K. Wagner
  • Edwin K. Jackson
Chapter

Abstract

Many secondary mechanisms regulate the evolution of damage and repair after traumatic brain injury (TBI). Bench-to-bedside studies from our team have shown that adenosine plays a key role in several secondary injury pathways in the brain, namely, excitotoxicity, neuroinflammation, and cerebral blood flow (CBF) dysregulation. Studies of adenosine A1-receptor (A1R) knockout (KO) mice strongly support a key role for adenosine-dependent effects at this receptor in attenuating posttraumatic excitotoxicty. A1R KO mice develop lethal status epilepticus after experimental TBI. Evidence also supports a role of the A1R in human TBI since A1R gene variants are associated with posttraumatic seizures in patients with TBI. A1R also modulates the neuroinflammatory response to TBI. A1R KO mice exhibit enhanced microglial proliferation early after TBI. Adenosine acting at A2A and/or A2B receptors also modulates posttraumatic CBF. Local injection of either the nonselective AR agonist 2-chloroadenosine or the A2AR agonist CGS21680 markedly increases CBF in naïve or brain-injured rats. However, whether the effects of adenosine on CBF after TBI are beneficial or detrimental is controversial. Mitigation of ischemia by adenosine produced from breakdown of ATP after TBI has been suggested, and consistent with this hypothesis, we reported increases in brain interstitial adenosine levels in patients with severe TBI during episodes of ischemia. However, in studies of CBF in patients after severe TBI, we also noted an association between cerebrospinal fluid (CSF) adenosine levels and uncoupling of CBF and metabolism (cerebral metabolic rate for oxygen [CMRO2]). Uncoupling of CBF and CMRO2 is associated with intracranial hypertension. Thus, adenosine may represent a two-edged sword after TBI. Additional evidence supporting a protective role of adenosine in TBI comes from clinical studies showing a powerful association between CSF caffeine levels and favorable outcome after TBI—given the interplay between caffeine and adenosine in neuroprotection. Finally, our work also suggests that the newly discovered 2,3-cyclic AMP pathway represents an important component of the adenosine response to TBI.

Keywords

Head injury Neuroinflammation Excitotoxicity Microglia Seizure Controlled cortical impact Cerebral blood flow Caffeine 

Notes

Acknowledgement

We thank the National Institutes of Neurological Disorders and Stroke NS070003 (PMK, EKJ) and the American Heart Association (JDV) for support.

References

  1. Akahane M, Ono H, Ohgushi H, Tamai S (2001) Viability of ischemia/reperfused muscles in rat: a new evaluation method by RNA degradation. J Orthop Res 19:559–564CrossRefPubMedGoogle Scholar
  2. Avsar E, Empson RM (2004) Adenosine acting via A1 receptors, controls the transition to status epilepticus-like behaviour in an in vitro model of epilepsy. Neuropharmacology 47:427–437CrossRefPubMedGoogle Scholar
  3. Bell MJ, Kochanek PM, Carcillo JA, Mi Z, Schiding JK, Wisniewski SR, Clark RS, Dixon CE, Marion DW, Jackson E (1998) Interstitial adenosine, inosine, and hypoxanthine are increased after experimental traumatic brain injury in the rat. J Neurotrauma 15:163–170CrossRefPubMedGoogle Scholar
  4. Bell MJ, Robertson CS, Kochanek PM, Goodman JC, Gopinath SP, Carcillo JA, Clark RS, Marion DW, Mi Z, Jackson EK (2001) Interstitial brain adenosine and xanthine increase during jugular venous oxygen desaturations in humans after traumatic brain injury. Crit Care Med 29:399–404CrossRefPubMedGoogle Scholar
  5. Bouma GJ, Muizelaar JP, Stringer WA, Choi SC, Fatouros P, Young HF (1992) Ultra-early evaluation of regional cerebral blood flow in severely head-injured patients using xenon-enhanced computerized tomography. J Neurosurg 77:360–368CrossRefPubMedGoogle Scholar
  6. Brain Trauma Foundation; American Association of Neurological Surgeons; Congress of Neurological Surgeons; Joint Section on Neurotrauma and Critical Care, AANS/CNS, Bratton SL, Chestnut RM, Ghajar J, McConnell Hammond FF, Harris OA, Hartl R, Manley GT, Nemecek A, Newell DW, Rosenthal G, Schouten J, Shutter L, Timmons SD, Ullman JS, Videtta W, Wilberger JE, Wright DW (2007) Guidelines for the management of severe traumatic brain injury. XIII. Antiseizure prophylaxis. J Neurotrauma 24 (suppl 1): S83–S86Google Scholar
  7. Catts VS, Catts SV, Fernandez HR, Taylor JM, Coulson EJ, Lutze-Mann LH (2005) A microarray study of post-mortem mRNA degradation in mouse brain tissue. Brain Res 138:164–177CrossRefGoogle Scholar
  8. Centers for Disease Control and Prevention. http://www.cdc.gov/TraumaticBrainInjury/statistics.html. Accessed 26 June 2011
  9. Chen JF, Pedata F (2008) Modulation of ischemic brain injury and neuroinflammation by adenosine A2A receptors. Curr Pharm Des 14:1490–1499CrossRefPubMedGoogle Scholar
  10. Chevyreva I, Faull RLM, Green CR, Nicholson LFB (2008) Assessing RNA quality in postmortem human brain tissue. Exp Mol Pathol 84:71–77CrossRefPubMedGoogle Scholar
  11. Clark RS, Carcillo JA, Kochanek PM, Obrist WD, Jackson EK, Mi Z, Wisneiwski SR, Bell MJ, Marion DW (1997) Cerebrospinal fluid adenosine concentration and uncoupling of cerebral blood flow and oxidative metabolism after severe head injury in humans. Neurosurgery 41:1284–1292, discussion 1292–1293CrossRefPubMedGoogle Scholar
  12. Clark RS, Schiding JK, Kaczorowski SL, Marion DW, Kochanek PM (1994) Neutrophil accumulation after traumatic brain injury in rats: comparison of weight drop and controlled cortical impact models. J Neurotrauma 11:499–506CrossRefPubMedGoogle Scholar
  13. Dai SS, Li W, An JH, Wang H, Yang N, Chen XY, Zhao Y, Li P, Liu P, Chen JF, Zhou YG (2010) Adenosine A2A receptors in both bone marrow cells and non-bone marrow cells contribute to traumatic brain injury. J Neurochem 113:1536–1544PubMedGoogle Scholar
  14. Dai SS, Zhou YG (2011) Adenosine 2A receptor: a crucial neuromodulator with bidirectional effect in neuroinflammation and brain injury. Rev Neurosci 22:231–239PubMedGoogle Scholar
  15. DeKosky ST, Ikonomovic MD, Gandy S (2010) Traumatic brain injury―football, warfare, and long-term effects. N Engl J Med 363:1293–1296CrossRefPubMedGoogle Scholar
  16. Del Prete MJ, Robles MS, Guao A, Martinez-A C, Izquierdo M, Garcia-Sanz JA (2002) Degradation of cellular mRNA is a general early apoptosis-induced event. FASEB J 16:2003–2005PubMedGoogle Scholar
  17. Dixon CE, Clifton GL, Lighthall JW, Yaghmai AA, Hayes RL (1991) A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Methods 39:253–262PubMedGoogle Scholar
  18. Fedele DE, Gouder N, Güttinger M, Gabernet L, Scheurer L, Rülicke T, Crestani F, Boison D (2005) Astrogliosis in epilepsy leads to overexpression of adenosine kinase, resulting in seizure aggravation. Brain 128:2383–2395CrossRefPubMedGoogle Scholar
  19. Foley LM, Hitchens TK, Ho C, Janesko-Feldman KL, Melick JA, Bayir H, Kochanek PM (2009) Magnetic resonance imaging assessment of macrophage accumulation in mouse brain after experimental traumatic brain injury. J Neurotrauma 26:1509–1519CrossRefPubMedGoogle Scholar
  20. Franklin PH, Zhang G, Tripp ED, Murray TF (1989) Adenosine A1 receptor activation mediates suppression of (-) bicuculline methiodide-induced seizures in rat prepiriform cortex. J Pharmacol Exp Ther 251:1229–1236PubMedGoogle Scholar
  21. Gopinath SP, Robertson CS, Contant CF, Hayes C, Feldman Z, Narayan RK, Grossman RG (1994) Jugular venous desaturation and outcome after head injury. J Neurol Neurosurg Psychiatry 57:717–723PubMedGoogle Scholar
  22. Gouder N, Scheurer L, Fritschy JM, Boison D (2004) Overexpression of adenosine kinase in epileptic hippocampus contributes to epileptogenesis. J Neurosci 24:692–701CrossRefPubMedGoogle Scholar
  23. Hall ED, Sullivan PG, Gibson TR, Pavel KM, Thompson BM, Scheff SW (2005) Spatial and temporal characteristics of neurodegeneration after controlled cortical impact in mice: more than a focal brain injury. J Neurotrauma 22:252–265CrossRefPubMedGoogle Scholar
  24. Haselkorn ML, Shellington DK, Jackson EK, Vagni VA, Janesko-Feldman K, Dubey RK, Gillespie DG, Cheng D, Bell MJ, Jenkins LW, Homanics GE, Schnermann J, Kochanek PM (2010) Adenosine A1 receptor activation as a brake on the microglial response after experimental traumatic brain injury in mice. J Neurotrauma 27:901–910CrossRefPubMedGoogle Scholar
  25. Hendrich KS, Kochanek PM, Williams DS, Schiding JK, Marion DW, Ho C (1999) Early perfusion after controlled cortical impact in rats: quantification by arterial spin-labeled MRI and the influence of spin-lattice relaxation time heterogeneity. Magn Reson Med 42:673–681CrossRefPubMedGoogle Scholar
  26. Hovda DA, Lee SM, Smith ML, Von Stuck S, Bergsneider M, Kelly D, Shalmon E, Martin N, Caron M, Mazziotta J et al (1995) The neurochemical and metabolic cascade following brain injury: moving from animal models to man. J Neurotrauma 12:903–906CrossRefPubMedGoogle Scholar
  27. Jackson EK, Gillespie DG, Dubey RK (2011a) 2′-AMP and 3′-AMP inhibit proliferation of preglomerular vascular smooth muscle cells and glomerular mesangial cells via A2B receptors. J Pharmacol Exp Ther 337:444–450CrossRefPubMedGoogle Scholar
  28. Jackson EK, Ren J, Cheng D, Mi Z (2011b) Extracellular cAMP-adenosine pathways in the mouse kidney. Am J Physiol Renal Physiol 301(3):F565–F573CrossRefPubMedGoogle Scholar
  29. Jackson EK, Ren J, Gillespie DG (2011c) 2′,3′-cAMP, 3′-AMP and 2′-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors. Am J Physiol Heart Circ Physiol 301(2):H391–H401CrossRefPubMedGoogle Scholar
  30. Jackson EK, Ren J, Gillespie DG, Dubey RK (2010) Extracellular 2′,3′-cyclic adenosine 5′-monophosphate is a potent inhibitor of preglomerular vascular smooth muscle cell and mesangial cell growth. Hypertension 56:151–158CrossRefPubMedGoogle Scholar
  31. Jackson EK, Ren J, Mi Z (2009) Extracellular 2′,3′-cAMP is a source of adenosine. J Biol Chem 284:33097–33106CrossRefPubMedGoogle Scholar
  32. Kochanek PM, Clark RS, Ruppel RA, Adelson PD, Bell MJ, Whalen MJ, Robertson CL, Satchell MA, Seidberg NA, Marion DW, Jenkins LW (2000) Biochemical, cellular, and molecular mechanisms in the evolution of secondary damage after severe traumatic brain injury in infants and children: lessons learned from the bedside. Pediatr Crit Care Med 1:4–19CrossRefPubMedGoogle Scholar
  33. Kochanek PM, Hendrich KS, Jackson EK, Wisniewski SR, Melick JA, Shore PM, Janesko KL, Zacharia L, Ho C (2005) Characterization of the effects of adenosine receptor agonists on cerebral blood flow in uninjured and traumatically injured rat brain using continuous arterial spin-labeled magnetic resonance imaging. J Cereb Blood Flow Metab 25:1596–1612CrossRefPubMedGoogle Scholar
  34. Kochanek PM, Vagni VA, Janesko KL, Washington CB, Crumrine PK, Garman RH, Jenkins LW, Clark RS, Homanics GE, Dixon CE, Schnermann J, Jackson EK (2006) Adenosine A1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 26:565–575CrossRefPubMedGoogle Scholar
  35. Kusano Y, Echeverry G, Miekisiak G, Kulik TB, Aronhime SN, Chen JF, Winn HR (2010) Role of adenosine A2 receptors in regulation of cerebral blood flow during induced hypotension. J Cereb Blood Flow Metab 30:808–815CrossRefPubMedGoogle Scholar
  36. Laghi Pasini F, Guideri F, Picano E, Parenti G, Petersen C, Varga A, Di Perri T (2000) Increase in plasma adenosine during brain ischemia in man: a study during transient ischemic attacks, and stroke. Brain Res Bull 51:327–330CrossRefPubMedGoogle Scholar
  37. Lalancette-Hébert M, Gowing G, Simard A, Weng YC, Kriz J (2007) Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain. J Neurosci 27:2596–2605CrossRefPubMedGoogle Scholar
  38. Li W, Dai S, An J, Li P, Chen X, Xiong R, Liu P, Wang H, Zhao Y, Zhu M, Liu X, Zhu P, Chen JF, Zhou Y (2008) Chronic but not acute treatment with caffeine attenuates traumatic brain injury in the mouse cortical impact model. Neuroscience 151:1198–1207CrossRefPubMedGoogle Scholar
  39. Li W, Dai S, An J, Xiong R, Li P, Chen X, Zhao Y, Liu P, Wang H, Zhu P, Chen J, Zhou Y (2009) Genetic inactivation of adenosine A2A receptors attenuates acute traumatic brain injury in the mouse cortical impact model. Exp Neurol 215:69–76CrossRefPubMedGoogle Scholar
  40. Lu G, Zhou QX, Kang S, Li QL, Zhao LC, Chen JD, Sun JF, Cao J, Wang YJ, Chen J, Chen XY, Zhong DF, Chi ZQ, Xu L, Liu JG (2010) Chronic morphine treatment impaired hippocampal long-term potentiation and spatial memory via accumulation of extracellular adenosine acting on adenosine A1 receptors. J Neurosci 30:5058–5070CrossRefPubMedGoogle Scholar
  41. McKee AC, Gavett BE, Stern RA, Nowinski CJ, Cantu RC, Kowall NW, Perl DP, Hedley-Whyte ET, Price B, Sullivan C, Morin P, Lee HS, Kubilus CA, Daneshvar DH, Wulff M, Budson AE (2010) TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol 69:918–929CrossRefPubMedGoogle Scholar
  42. Miller LP, Hsu C (1992) Therapeutic potential for adenosine receptor activation in ischemic brain injury. J Neurotrauma 9 (Suppl 2): S563–S577CrossRefPubMedGoogle Scholar
  43. Ngai AC, Coyne EF, Meno JR, West GA, Winn HR (2001) Receptor subtypes mediating adenosine-induced dilation of cerebral arterioles. Am J Physiol Heart Circ Physiol 280:H2329–H2335PubMedGoogle Scholar
  44. RAND invisible wounds of war study. http://www.rand.org/multi/military/veterans.html. Accessed 26 June 2011
  45. Ren J, Mi Z, Stewart NA, Jackson EK (2009) Identification and quantification of 2′,3′-cAMP release by the kidney. J Pharmacol Exp Ther 328:855–865CrossRefPubMedGoogle Scholar
  46. Robertson CL, Bell MJ, Kochanek PM, Adelson PD, Ruppel RA, Carcillo JA, Wisniewski SR, Mi Z, Janesko KL, Clark RS, Marion DW, Graham SH, Jackson EK (2001) Increased adenosine in cerebrospinal fluid after severe traumatic brain injury in infants and children: association with severity of injury and excitotoxicity. Crit Care Med 29:2287–2293CrossRefPubMedGoogle Scholar
  47. Saatman KE, Duhaime AC, Bullock R, Maas AI, Valadka A, Manley GT, Workshop Scientific Team and Advisory Panel Members (2008) Classification of traumatic brain injury for targeted therapies. J Neurotrauma 25:719–738CrossRefPubMedGoogle Scholar
  48. Sachse KT, Jackson EK, Wisniewski SR, Gillespie DG, Puccio AM, Clark RS, Dixon CE, Kochanek PM (2008) Increases in cerebrospinal fluid caffeine concentration are associated with favorable outcome after severe traumatic brain injury in humans. J Cereb Blood Flow Metab 28:395–401CrossRefPubMedGoogle Scholar
  49. Saharan RS, Nantwi KD (2006) Changes in the biochemical profiles of mid-cervically located adenosine A1 receptors after repeated theophylline administration in adult rats. J Spinal Cord Med 29:520–526PubMedGoogle Scholar
  50. Sinz EH, Kochanek PM, Heyes MP, Wisniewski SR, Bell MJ, Clark RS, DeKosky ST, Blight AR, Marion DW (1998) Quinolinic acid is increased in CSF and associated with mortality after traumatic brain injury in humans. J Cereb Blood Flow Metab 18:610–615CrossRefPubMedGoogle Scholar
  51. Sprinkle TJ (1989) 2′,3′-cyclic nucleotide 3′-phosphodiesterase, an oligodendrocyte-Schwann cell and myelin-associated enzyme of the nervous system. Crit Rev Neurobiol 4:235–301PubMedGoogle Scholar
  52. Synowitz M, Glass R, Färber K, Markovic D, Kronenberg G, Herrmann K, Schnermann J, Nolte C, van Rooijen N, Kiwit J, Kettenmann H (2006) A1 adenosine receptors in microglia control glioblastoma-host interaction. Cancer Res 66:8550–8557CrossRefPubMedGoogle Scholar
  53. Tsutsui S, Schnermann J, Noorbakhsh F, Henry S, Yong VW, Winston BW, Warren K, Power C (2004) A1 adenosine receptor upregulation and activation attenuates neuroinflammation and demyelination in a model of multiple sclerosis. J Neurosci 24:1521–1529CrossRefPubMedGoogle Scholar
  54. Varma MR, Dixon CE, Jackson EK, Peters GW, Melick JA, Griffith RP, Vagni VA, Clark RS, Jenkins LW, Kochanek PM (2002) Administration of adenosine receptor agonists or antagonists after controlled cortical impact in mice: effects on function and histopathology. Brain Res 951:191–201CrossRefPubMedGoogle Scholar
  55. Verrier JD, Exo JL, Jackson TC, Ren J, Gillespie DG, Dubey RK, Kochanek PM, Jackson EK (2011) Robust expression of the 2′,3′-cAMP-adenosine pathway, but not the 3′,5′-cAMP-adenosine pathway, in microglia. J Neurochem 118:979–987Google Scholar
  56. Vespa PM, Miller C, McArthur D, Eliseo M, Etchepare M, Hirt D, Glenn TC, Martin N, Hovda D (2007) Nonconvulsive electrographic seizures after traumatic brain injury result in a delayed, prolonged increase in intracranial pressure and metabolic crisis. Crit Care Med 35:2830–2836CrossRefPubMedGoogle Scholar
  57. Wagner AK, Miller MA, Scanlon J, Ren D, Kochanek PM, Conley YP (2010) Adenosine A1 receptor gene variants associated with post-traumatic seizures after severe TBI. Epilepsy Res 90:259–272CrossRefPubMedGoogle Scholar
  58. Yu L, Huang Z, Mariani J, Wang Y, Moskowitz M, Chen JF (2004) Selective inactivation or reconstitution of adenosine A2A receptors in bone marrow cells reveals their significant contribution to the development of ischemic brain injury. Nat Med 10:1081–1087CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  • Patrick M. Kochanek
    • 1
    Email author
  • Jonathan D. Verrier
    • 2
  • Amy K. Wagner
    • 3
  • Edwin K. Jackson
    • 2
  1. 1.Department of Critical Care MedicineUniversity of Pittsburgh School of MedicinePittsburghUSA
  2. 2.Department of Pharmacology and Chemical BiologyUniversity of Pittsburgh School of MedicinePittsburghUSA
  3. 3.Department of Physical Medicine & RehabilitationUniversity of Pittsburgh School of MedicinePittsburghUSA

Personalised recommendations